Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0

TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder
April 19, 2022 at 8:00 AM EDT
Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts
Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat COVID-19

UNION Therapeutics A/S has an option to exclusively license the dry powder formulation of niclosamide, in which case it would take over responsibility for further development.

I hear UNION has 45 day period to excercise their option to develop...

Under the agreement, UNION will pay TFF up to 210 million USD related to option exercise, development and commercial milestones, as well as tiered single-digit royalties on product sales.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.